TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorSantos, C.
dc.contributor.authorLawrence, P.
dc.contributor.authorLopez-Doriga, A.
dc.contributor.authorRagulan, C.
dc.contributor.authorFontana, E.
dc.contributor.authorDesai, K.
dc.contributor.authorPs, H.
dc.contributor.authorElez Fernandez, M. E.
dc.contributor.authorAranda Aguilar, E.
dc.contributor.authorLosa, F.
dc.contributor.authorPaez, D.
dc.contributor.authorLayos Romero, L.
dc.contributor.authorSanjuan, X.
dc.contributor.authorCanas, M. A.
dc.contributor.authorAzuara, D.
dc.contributor.authorQueralt, B.
dc.contributor.authorFernandez-Calotti, P.
dc.contributor.authorSalazar, R.
dc.contributor.authorSadanandam, A.
dc.contributor.authoraffiliation[Santos, C.] Hosp Duran & Reynals, ICO Inst Catala dOncol, Av Gran Via LHosp 199-203, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Azuara, D.] Hosp Duran & Reynals, ICO Inst Catala dOncol, Av Gran Via LHosp 199-203, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Fernandez-Calotti, P.] Hosp Duran & Reynals, ICO Inst Catala dOncol, Av Gran Via LHosp 199-203, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Lawrence, P.] Inst Canc Res, Lab Syst & Precis Canc Med, London, England
dc.contributor.authoraffiliation[Ragulan, C.] Inst Canc Res, Lab Syst & Precis Canc Med, London, England
dc.contributor.authoraffiliation[Ps, H.] Inst Canc Res, Lab Syst & Precis Canc Med, London, England
dc.contributor.authoraffiliation[Lopez-Doriga, A.] Hosp Duran & Reynals, ICO Inst Catala dOncol, Oncol Data Analyt Program, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Fontana, E.] SCRI Sarah Cannon Res Inst, London, England
dc.contributor.authoraffiliation[Fontana, E.] UCL, Canc Inst, London, England
dc.contributor.authoraffiliation[Desai, K.] ICR Inst Canc Res North Site, Ctr Mol Pathol, Sutton, Surrey, England
dc.contributor.authoraffiliation[Sadanandam, A.] ICR Inst Canc Res North Site, Ctr Mol Pathol, Sutton, Surrey, England
dc.contributor.authoraffiliation[Elez Fernandez, M. E.] Vall dHebron Univ Hosp, Inst dOncol, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Aranda Aguilar, E.] Univ Hosp Reina Sofia, Med Oncol Dept, Cordoba, Spain
dc.contributor.authoraffiliation[Losa, F.] Hosp Sant Joan Despi Moises Broggi, ICO Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Paez, D.] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Layos Romero, L.] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Dept, Badalona, Spain
dc.contributor.authoraffiliation[Sanjuan, X.] Hosp Univ Bellvitge, Pathol Dept, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Canas, M. A.] Hosp San Joan Despi Moises Broggi, Pathol Dept, San Joan Despi, Spain
dc.contributor.authoraffiliation[Queralt, B.] ICO Inst Catala dOncol, Med Oncol Dept, Girona, Spain
dc.contributor.authoraffiliation[Salazar, R.] Hosp Duran & Reynals, Inst Catala dOncol, Oncol Dept, Lhospitalet De Llobregat, Spain
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2025-01-07T13:41:08Z
dc.date.available2025-01-07T13:41:08Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.999
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753421032282/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25751
dc.identifier.wosID700527700456
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.numberS570-S570
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleTA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía